<DOC>
	<DOCNO>NCT00308178</DOCNO>
	<brief_summary>The purpose trial see Abraxane , new form paclitaxel , safe replacement form paclitaxel dose-dense chemotherapy . This trial also determine use Abraxane allow patient receive treatment every two week without require injects G-CSF , white blood cell stimulate growth factor .</brief_summary>
	<brief_title>Dose Dense Abraxane Adjuvant Chemotherapy Breast Cancer</brief_title>
	<detailed_description>- Patients receive regular chemotherapy every 2 week 8 cycle ( approximately 16 week total ) treatment . During first four cycle patient treat Adriamycin Cytoxan , second four cycle treat Abraxane . - Patients taught give injection either short long act G-CSF prescribed doctor first four cycle chemotherapy . During last four cycle ( patient take Abraxane ) receive G-CSF unless low blood count . - If patient HER-2 positive breast cancer , also receive 52 week Herceptin part standard cancer care begin receive Herceptin time begin Abraxane ( 4 cycle adriamycin cytoxan treatment ) . - This study involve series Quality Life Questionnaires complete prior beginning study treatment , 2 month , 4 month , 6 month , 1 year start study treatment . - The following test procedure perform time period specify . Cycle 1-4 Day 1 : Physical exam , vital sign , blood test . Cycle 5 Day 1 : Physical exam , vital sign , blood test , RVG ( measurement heart function ) questionnaire . Cycle 6 &amp; 7 Day 1 : Physical exam , vital sign , blood test . Cycle 8 Day 1 : physical exam , vital sign , blood test , questionnaire . Follow-up ( 6 month 1 year cycle 1 day 1 ) : questionnaire .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Histologically cytologically confirm breast cancer , clinical stage I , II , III disease Must register begin adjuvant neoadjuvant chemotherapy 18 year age old ECOG performance status 0 1 Normal organ marrow function Previous cytotoxic chemotherapy therapeutic radiation therapy reason Pregnant nursing Receiving investigational agent Patients Stage IV breast cancer Current grade II great peripheral neuropathy prior history grade II great neuropathy Uncontrolled intercurrent illness , include limited , ongoing active infection , symptomatic congestive heart failure , uncontrolled hypertension , unstable angina pectoris , cardiac arrythmia , psychiatric illness/social situation would limit compliance study requirement Immune deficiency treat marrowsuppressive therapy HIVpositive patient receive antiretroviral therapy Patients sickle cell disease Known history hyperviscosity syndrome Patients lithium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Abraxane</keyword>
	<keyword>dose-dense chemotherapy</keyword>
	<keyword>taxol</keyword>
</DOC>